China Ebola vaccine gets nod for overseas clinical trial; WuXi launches oncology app;

> A Chinese-developed Ebola vaccine has for the first time been approved for an overseas clinical trial, according to a report in the People's Daily by state-owned news agency Xinhua. The Phase II clinical trial in Sierra Leone started on Oct. 11, the report said. Report

> WuXi PharmaTech ($WX) announced it has launched a mobile application available for Android and iOS devices that will allow researchers access to oncology models on their tablets and mobile phones. The mobile version of the company's OncoWuXi application provides a portable oncology database of the more than 1,000 cancer patient-derived xenograft (PDX), human cancer cell-derived xenograft (CDX) and syngeneic mouse tumor models available at WuXi, the company said in a release. Users may also submit service requests regarding particular models from the app directly to WuXi Oncology. Release

> Pfizer ($PFE) India Managing Director Aijaz Tobaccowalla has resigned from his position, India's Economic Times reported, saying the company's day-to-day operations will be managed by the executive director of its business unit and distribution S. Sridhar until the post is filled. Tobaccowalla's resignation becomes effective Oct. 16. Report

> India has gone on record as being opposed to proposed European trademark rules that could let EU customs officials seize goods in transit if there were suspected trademark violations, according to a Livemint report. Indian officials said they were concerned EU officials would seize low-cost generics headed for African and Latin American countries at EU ports. India and the EU have a history of tussles over generic drugs. In 2008, there were 17 cases of medicine seizure in the Netherlands alone, according to the Livemint report. Report

> The Indian state government of Jharkhand said it will start buying medicines from other states to deal with drug shortages affecting the state and would introduce reverse bidding to cut down on the time it takes to procure drugs, the Times of India reported. The newly formed Jharkhand Medical and Health Infrastructure Development and Procurement Corporation will start functioning by October and is entitled to buy drugs in bulk from other state corporations in times of need. Report

> China Jo-Jo Drugstores ($CJJD) said in a press release its online pharmacy sales grew an astounding 438% in the first half of its fiscal 2016 financial year and its gross profit margin was 25%. The company said sales were driven by four product sectors including medical devices, OTC drugs, toiletries and nutritional supplements. Release

> China's Shanghai Fosun Long March Medicine Science has signed a deal with U.S.-based Astute Medical for distribution of Astute's NephroCheck Test on the Astute140 Meter in China. Release

> China biotech BeiGene has dosed the first patient in a China Phase I for BGB-283, a novel RAF dimer inhibitor for the treatment of solid tumors harboring B-RAF mutations and other aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway. The study is being conducted across multiple centers in China. Release (PDF)

> China-focused CASI Pharmaceuticals ($CASI) said its oncology drug candidate ENMD-2076 has received Orphan Drug designation from the European Medicines Agency in the treatment of hepatocellular carcinoma. Release